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Background: Our knowledge of thymic malignancies has largely been 
derived from small, single-institution series. Recognition of the need 
for broad collaboration led to the creation of the International Thymic 
Malignancy Interest Group (ITMIG) and the development of a large, 
centralized database to advance knowledge of these rare tumors.
Methods: A multidisciplinary Database Committee was convened 
to define a common set of data elements a priori. Retrospective data 
were solicited from ITMIG members and collated using standardized 
fields. Patients with thymoma, thymic carcinoma, or thymic carci-
noid were included.
Results: Over a 6-month period, 47 institutions spanning 15 countries 
contributed a total of 6097 cases (mean, 129 [range, 10–1209]). The sex 
distribution was equal for thymomas, but there was a greater propor-
tion of men with thymic carcinoma and thymic carcinoid (p < 0.0001). 
Nearly all cases (99%) were treated surgically. WHO type B2 was the 
most frequent histologic classification among thymomas, whereas 
squamous was the most common among thymic carcinomas. In total, 
38% of patients with thymoma had myasthenia gravis compared with 
less than or equal to 5% for thymic carcinoma and thymic carcinoid. 
Median overall survival was 18.9 years (95% confidence interval [CI], 
17.4–20.3) for thymoma, 6.8 years (95% CI, 5.5–7.9) for thymic carci-
noma, and 7.5 years (95% CI, 6.5–8.5) for thymic carcinoid.
Conclusions: The rapid creation of the ITMIG database demon-
strates the feasibility of international collaboration for this rare set of 
malignancies and attests to the engagement of its membership. This 
database represents the largest collective data set ever assembled and 
provides an unprecedented resource for research of these tumors.
Key Words: Thymoma, Thymic carcinoma, Thymic carcinoid, 
Database, Thymic malignancies.
(J Thorac Oncol. 2014;9: 1573–1578)
Thymic malignancies are uncommon tumors whose unusual behavior and association with immunologic derangements 
have long captivated clinicians. Few prospective studies have 
been conducted, and our knowledge is largely derived from small, 
dated series. The seminal report by Masaoka et al.,1 whose epony-
mous classification was based on only 96 patients, appeared more 
than three decades ago. Given the rarity of these malignancies, 
meaningful advancement requires international collaboration.2
The International Thymic Malignancy Interest Group 
(ITMIG) arose from the recognition of this need.3 One of its 
central priorities was the collection of worldwide data and the 
development of a centralized database. The precedent of the 
International Association for the Staging of Lung Cancer stag-
ing project provided a model for collaboration,4 and the need 
for more data to inform the development of a formal staging 
classification served as a major driver for this project.5
This database was also intended as a resource for the 
investigation of clinical issues, including histology, treatment, 
prognosis, autoimmune disease, and second malignancies. 
Existing population-based registries are limited in their utility 
for addressing these specific questions,6 and this effort was 
aimed at enriching data collection with greater detail. This 
article provides an overview of the ITMIG database, its con-
tents, and the process behind its creation.
PATIENTS AND METHODS
The ITMIG Database Committee has broad representa-
tion, including surgery, medical oncology, radiation oncology, 
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radiology, pathology, and information technology across North 
America, Europe, and Asia. The committee was assigned the 
tasks of defining the relevant data elements and identifying a 
suitable provider to create the data infrastructure.
A collaboration between ITMIG and Purdue University 
created the data structure, using the HUBzero platform and the 
Purdue Cancer Center Engineering project.7 This created an 
open-source, Health Insurance Portability and Accountability 
Act-compliant infrastructure with flexibility for future expan-
sion as a centralized hub for scientific discourse among 
ITMIG members.
Existing retrospective data were collected from estab-
lished institutional databases worldwide. A common set of 
data elements was defined in collaboration with the Japanese 
Association for Research of the Thymus, the European 
Society of Thoracic Surgeons, and the Chinese Association 
for Research of the Thymus (Supplemental Appendix 1, 
Supplemental Digital Content, http://links.lww.com/JTO/
A637). The database includes patients diagnosed with thy-
moma, thymic carcinoma, or thymic carcinoid. To achieve 
consistency, the data elements build on the standard definitions 
developed by ITMIG,8 the Masaoka or Masaoka-Koga stage 
classification systems,1,9 the World Health Organization histo-
logic classification,10 and the Myasthenia Gravis Foundation 
of America classification of myasthenia gravis severity.11
Patient characteristics were compared using two-tailed 
t tests for continuous variables and χ2 and Fisher’s exact tests 
for categorical variables. Survival was measured from the first 
date of treatment to the date of death or last follow-up, and 
curves were generated using the Kaplan-Meier method.
RESULTS
From September 2012 to February 2013, a total of 6097 
cases were submitted from 47 institutions across 15 countries 
spanning North America, South America, Europe, and Asia. 
The tasks of cleaning, standardization, clarification of missing 
or nonsensical entries, and aggregation of data were completed 
by August 2013. The contributing centers are listed in Table 1 
and Figure 1. Institutions contributed a mean of 129 cases 
(range, 10–1209). Basic demographic characteristics are listed 
in Table 2. Most of the cases were diagnosed between 2000 and 
2010. The mean age was similar among patients with thymoma, 
thymic carcinoma, and thymic carcinoid; however, whereas sex 
distribution was equal among patients with thymoma, there was 
a greater proportion of men among those with thymic carci-
noma (p < 0.0001) and thymic carcinoid (p < 0.0001).
Histologic Classification
The histologic distribution is listed in Table 3; B2 was 
the most common histologic classification reported. Among 
patients with thymic carcinoma, squamous was the most com-
mon histologic classification reported. The distribution of 
Masaoka stage is listed in Table 4. In some cases, Masaoka (or 
Masaoka-Koga) stage was provided without further subdivision 
into A or B subcategories (stages II and IV). A majority had 
early-stage tumors (Masaoka I or II), but a substantial num-
ber of stage III (n = 1167) and IV (n = 673) cases were also 
captured.
Autoimmune Disease
Autoimmune disease was reported in one-third of all 
patients with thymic malignancies and was primarily limited 
to patients with thymoma (Table 5). In total, nearly 38% of 
patients with thymoma had myasthenia gravis. Other para-
neoplastic syndromes, such as hypogammaglobulinemia and 
red cell aplasia, were exceedingly rare, with each representing 
less than 1% of thymoma cases. Autoimmune disease was also 
rare among patients with thymic carcinoma and thymic car-
cinoid, with nearly all involving myasthenia gravis (n = 36).
Treatment
The vast majority of submitted cases were treated at 
initial diagnosis with surgery as primary therapy (Fig. 2). 
Adjuvant radiotherapy was administered to 1664 patients 
(42%), and a minority of patients received neoadjuvant ther-
apy, either chemotherapy (11%) or radiotherapy (2%). Less 
than 1% of cases received palliative chemotherapy (n = 27) or 
radiotherapy (n = 7) only.
Outcomes
Vital status was available for 4821 cases (79%), with 904 
deaths (19%). Recurrence status was available for 4101 cases 
(67%), 715 of whom experienced relapse (17%). Information 
on cause of death was available for 526 cases: 325 (62%) died 
TABLE 1.  Contributing Institutions by Country
Country Institution(s)
Argentina Alexander Fleming Institute, Maria Ferrer Institute
Belgium Antwerp University, University Hospitals Leuven
China Beijing Cancer Hospital, Henan Cancer Hospital, 
Shanghai Chest Hospital, Shanghai Pulmonary 
Disease Hospital, Sichuan Cancer Hospital, Tianjin 
Cancer Hospital
Denmark Rigshospitalet University Hospital
France Louis Pradel Hospital
Germany Klinik Schillerhoehe, Mannheim University
Greece AHEPA University
Italy Hospital Riuniti, Ancona; Regina Elena National Cancer 
Institute, Rome; S. Croce e Carle Hospital, Cuneo; 
University of Catania; University of Napoli Federico 
II; University of Padua; University of Pisa; University 
of Torino
Korea Gangnam Severance Hospital, Seoul National Hospital, 
Severance Hospital
Netherlands Maastricht University
Romania Fundeni Clinical Institute Bucharest
Spain Hospital Mutua de Terrassa
Turkey Istanbul Medical University
United Kingdom Birmingham Heartlands Hospital, Guy’s and St. Thomas 
Hospital, Royal Brompton & Harefield
United States Fox Chase, Hackensack University Medical Center, 
Indiana University, Massachusetts General Hospital, 
Mayo Clinic, MD Anderson Cancer Center, 
Memorial Sloan Kettering, Oregon Health and 
Science University, Penn Presbyterian Medical 
Center, Stanford University, Swedish Medical Center, 
University of Chicago, Yale University
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of tumor-related causes (including myasthenia-related com-
plications), 36 (7%) died of treatment-related causes, and 165 
(31%) died of nontumor-related causes (Fig. 3). Survival was 
calculable for 4009 patients. Median survival was 18.9 years 
(95% confidence interval [CI], 17.4–20.3) for patients with 
thymoma, 6.8 years (95% CI, 5.5–7.9) for patients with thy-
mic carcinoma, and 7.5 years (95% CI, 6.5–8.5) for patients 
with thymic carcinoid (Fig. 4).
DISCUSSION
The ITMIG International Database represents the 
largest data set of thymic malignancies ever compiled and 
FIGURE 1.  Geographic distribution of contribut-
ing centers to the ITMIG database.
TABLE 2.  Demographic Characteristics
Characteristic All Thymoma
Thymic 
Carcinoma
Thymic 
Carcinoid
Total 6097 4918 848 160
Age, years,  
mean (SD)
54.0 (14) 53.9 (14) 55.2 (14) 54.7 (12.5)
Male, no. (%) 3088 (51) 2365 (48) 507 (60) 121 (76)
TABLE 3.  Distribution of WHO Histologic Profiles
Diagnosis, WHO Profile No. (%)
Thymoma 4529
  A 497 (11)
  AB 1026 (23)
  B1 737 (16)
  B2 1273 (28)
  B3 894 (20)
  Micronodular 87 (2)
  Metaplastic 15 (<1)
Thymic carcinoma 602
  Squamous 481 (80)
  Lymphoepithelioma-like 36 (6)
  Basaloid 19 (3)
  Undifferentiated 16 (3)
  Sarcomatoid 12 (2)
  Adenocarcinoma 11 (2)
  Mucoepidermoid 9 (1)
  Clear cell 8 (1)
  Other 10 (2)
TABLE 4.  Distribution of Masaoka Stage
Stage No. (%)
I 1582 (32)
II 424 (9)
IIa 581 (12)
IIb 560 (11)
III 1167 (23)
IV 45 (1)
IVa 371 (7)
IVb 257 (5)
Total 4987
II and IV are cases submitted with a and b subclassification.
TABLE 5.  Paraneoplastic Syndromes
Syndrome Thymoma
Thymic 
Carcinoma
Thymic  
Carcinoid
None 2623 (61) 607 (95) 119 (96)
Myasthenia gravis 1634 (38) 31 (5) 5 (4)
Hypogammaglobulinemia 13 (<1) 1 (<1) 0 (0)
Red cell aplasia 37 (1) 1 (<1) 0 (0)
Not available 611 (14) 208 (33) 36 (29)
Data are no. (%).
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provides an unprecedented resource for inquiry. To stimulate 
research, this article provides investigators with an overview 
of the contents of the database, including the demographic 
characteristics, management, and outcomes of these patients. 
The number of institutions and cases speaks to the depth of 
interest and feasibility of international collaboration to study 
these orphan diseases. That the project was accomplished in 
less than 6 months is a testament to the broad support that has 
propelled the growth of ITMIG.3
The prolonged survival observed appears to suggest a 
better prognosis than previously demonstrated. Even among 
the more aggressive tumors, such as thymic carcinomas and 
carcinoids, median survival approached 7 years. The larg-
est previous experience, of 1320 cases from Japan, noted a 
median survival of just over 5 years.12 Whether the difference 
in survival is a function of better treatment, diagnosis, or data 
remains unknown. Our findings support the notion that refo-
cusing on recurrence instead of survival may be more clini-
cally useful.8
Whether these outcomes should justify more-extensive 
treatment or support less-aggressive strategies is unclear. 
Small series have demonstrated the feasibility of extended 
resections13; yet, nonsurgical approaches have also led to pro-
longed survival.14 Nevertheless, of the patients with known 
cause of death, two-thirds ultimately died of disease-related 
causes, suggesting there is still room for improvement.
Although the data set contains few nonsurgical cases, 
a substantial number received multimodality treatment, 
FIGURE 2.  Treatment modalities. 
FIGURE 3.  Causes of death (n = 526).
FIGURE 4.  Overall survival by tumor type.
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including adjuvant radiation. The utility of this strategy 
remains controversial, and a recent meta-analysis suggested 
no benefit.15 The inclusion of over 1600 cases with adjuvant 
radiation in the database presents a unique opportunity to 
study this question.
The incidence of myasthenia gravis associated with 
thymoma in our analysis (38%) was somewhat higher than in 
other reports, such as 25% among 1089 Japanese patients with 
thymoma.12 However, less than 1% of our patients had hypo-
gammaglobulinemia or red cell aplasia. These less common 
autoimmune disorders may be underreported in the ITMIG 
database.
Selection bias and other limitations are inherent in the 
ITMIG database. The data on patients managed nonsurgically 
are limited, and information on patients at the margins—the 
metastatic, medically inoperable, and unresectable patients—
is lacking. Missing data are inevitable in any large but volun-
tary collaborative efforts. Centralized pathologic review was 
not feasible in this retrospective setting, but our data reflect 
histologic classification in actual practice.
The ITMIG database offers investigators a large and 
rich data set for research. Contributors to the database are 
invited to submit research proposals to ITMIG. Approved 
projects will be conducted in coordination with a statistical 
core in ITMIG to facilitate data selection and analysis. The 
first series of analyses is nearing completion. In keeping with 
the collaborative culture of ITMIG, we encourage investiga-
tors posing similar questions to join together.
The ITMIG International Database is only one part of 
the foundation for collaborative research in thymic malignan-
cies. It provides the basis for the first official stage classifi-
cation system, a fundamental necessity for further progress.5 
Insights gained from the retrospective analysis will clarify our 
knowledge gaps and inform further queries. Accrual to a more 
detailed prospective database is now under way, and innova-
tive approaches such as Bayesian analysis are being explored. 
Since the inception of ITMIG in 2010, major strides have been 
made in developing infrastructure across international bound-
aries. It is the hope of ITMIG that the International Database 
will provide another step toward advancing our understanding 
of these orphan diseases.
APPENDIX 1: LIST OF ITMIG INTERNATIONAL 
DATABASE CONTRIBUTORS
Argentina: Moises Rosenberg, Alexander Fleming Institute 
and Maria Ferrer Institute.
Belgium: Paul Van Schil, Antwerp University; Hans Van Veer, 
University Hospitals Leuven.
China: Wentao Fang, Shanghai Chest Hospital; Gu Zhi 
Tao, Shanghai Chest Hospital, Henan Cancer Hospital, 
Tianjin Cancer Hospital, Beijing Cancer Hospital, Shanghai 
Pulmonary Disease Hospital, and Sichuan Cancer Hospital.
Denmark: Kristoffer Staal Rohrberg and Gedske Daugaard, 
Rigshospitalet University Hospital.
France: Nicolas Girard, Louis Pradel Hospital.
Germany: Philipp Strobel and Alexander Marx, Mannheim 
University; Martin Kimmich, Klinik Schillerhoehe.
Greece: Christophoros N. Foroulis, AHEPA University.
Italy: Salvatore Saita, Azienda Ospedaliero-Universitaria 
Policlinico V. Emanuele; Luca Bertolaccini, Azienda Ospedaliera 
S. Croce e Carle; Mirella Marino, Regina Elena National Cancer 
Institute; Giovanella Palmieri and Carlo Buonerba, Universita’ 
degli Studi di Napoli Federico II; Giuseppe Marulli, University 
of Padua; Marco Lucchi and Anna De Rosa, University of Pisa; 
Alessandro Brunelli, Ospedali Riuniti, Ancona, Italy.
Korea: Seok Jin Haam, Gangnam Severance Hospital; Mi 
Kyung Bae, Severance Hospital; In Kyu Park, Seoul National 
Hospital.
Netherlands: Marlies Keijzers, Maastricht University.
Romania: Victor Nicolae Tomulescu, Fundeni Clinical 
Institute, Bucharest.
Spain: Sergi Call Caja and Juan Carlos Trujillo, Hospital 
Mutua de Terrassa.
Turkey: Alper Toker and Saut Erus, Istanbul Medical 
University.
United Kingdom: Maninder Singh Kalkat, Birmingham 
Heartlands Hospital; Andrew G. Nicholson and Eric Lim, 
Royal Brompton Hospital & Harefield NHS Foundation Trust; 
Loic Lang-lazdunski and Andrea Billé, Guy’s and St Thomas 
Hospital.
United States: Frank Detterbeck, Yale University; Daniel 
R. Gomez and Edith Marom, MD Anderson Cancer Center; 
Heather Wakelee, Stanford University; Eric Vallieres, 
Swedish Medical Center; Walter Scott and Stacey Su, Fox 
Chase; Bernard Park and Jennifer Marks, Hackensack 
University Medical Center; Sami Khella, Penn Presbyterian 
Medical Center; Robert Shen, Mayo Clinic; James Huang, 
Memorial Sloan Kettering Cancer Center; Cameron Wright, 
Massachusetts General Hospital; Mark Ferguson, University 
of Chicago; Patrick Loehrer, Indiana University; Jesse 
Wagner, Oregon Health and Science University.
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